ACW 59.2% 3.1¢ actinogen medical limited

Ann: ACW XanaCIDD phase 2a trial topline results, page-55

  1. 3 Posts.
    Agree about trial design. The attention composite results seem completely inconclusive in my opinion, not necessarily as negative as the market is reacting however. The 2 groups of patients start nowhere near each other and that placebo effect seems unprecedented and not very well explained by ACW team, if it remained in expected range we would have a winner. Follow up shows placebo group start decreasing while xanemem continue to improve so that seems good at least. Other indicators seem positive. Overall disappointed by the trial results but ultimately not discouraged.
    Last edited by Sonarks: Yesterday, 12:03
 
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Last
3.1¢
Change
-0.045(59.2%)
Mkt cap ! $84.06M
Open High Low Value Volume
3.0¢ 3.7¢ 2.5¢ $3.093M 99.90M

Buyers (Bids)

No. Vol. Price($)
5 2638151 3.1¢
 

Sellers (Offers)

Price($) Vol. No.
3.2¢ 1623309 5
View Market Depth
Last trade - 16.10pm 12/08/2024 (20 minute delay) ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.